Israel’s Teva Pharmaceutical Industries today announced the availability of an autoinjector device for Ajovy fremanezumab-vfrm), a preventive treatment of migraine in adults that thus far was available as a pre-filled syringe. 27 April 2020
UK-based biotech Touchlight has appointed Helen Horton, formerly a senior scientific director at Johnson & Johnson, as chief research officer. 27 April 2020
Novartis today announced that the US Food and Drug Administration granted Regenerative Medicine Advanced Therapy (RMAT) designation to Kymriah (tisagenlecleucel), for an investigational new indication to treat patients with relapsed or refractory (r/r) follicular lymphoma (FL). 22 April 2020
The US regulator will review a submission from Bristol Myers Squibb to broaden the label for Opdivo (nivolumab) and Yervoy (ipilimumab), plus chemo, for certain people with non-small cell lung cancer (NSCLC). 8 April 2020
Danish CNS specialist Lundbeck’s Vyepti (eptinezumab-jjmr), the first and only intravenous (IV) treatment for migraine prevention, is now commercially available in the USA and can be obtained via select specialty distributors and specialty pharmacies. 6 April 2020
US biotech Seneca Biopharma today announced the completion of its new cell manufacturing facility in Suzhou, China, with the news sending the firm’s shares 14.64% higher to $0.69 by late morning Nasdaq trading. 3 April 2020
ImaginAb, a USA-based clinical stage immuno-oncology imaging company, today announced it has signed a multi-year non-exclusive license agreement with AstraZeneca. 30 March 2020
Canadian biopharma Bold Therapeutics, which is usually focused on developing anti-cancer drugs, has announced that its lead drug BOLD-100 could be a useful antiviral agent in the fight against COVID-19. 27 March 2020
East-Coast, USA-based Orphan Technologies has been granted rare pediatric disease (RPD) designation from the US regulator for its candidate OT-58, for the treatment of cystathionine beta synthase deficiency homocystinuria. 27 March 2020
Privately-held Switzerland-headquartered Ewopharma has acquired rights to commercialize Japanese drugmaker Eisai’s Lenvima(lenvatinib) in Central and Eastern Europe (CEE). 26 March 2020
Swiss firm Urovant Sciences has appointed Jim Robinson as chief executive, replacing the firm’s founding CEO Keith Katkin, who will become an advisor. 24 March 2020
USA-based Valeritas Holdings today announced that the US Bankruptcy Court for the District of Delaware approved the sale of substantially all of the business to Danish biotech firm Zealand Pharma. 20 March 2020
Novartis has picked up Japanese approval for its one-time gene therapy Zolgensma (onasemnogene abeparvovec), for spinal muscular atrophy (SMA) in young children. 19 March 2020
Cambridge, Massachusetts, USA-based biotech Kymera Therapeutics, which is pioneering targeted protein degradation to invent breakthrough protein degrader medicines for patients, today announced the closing of a $102 million Series C financing. 12 March 2020
Danish biotech Genmab says that Anthony Mancini will join the company on March 23 as executive vice president and chief operating officer, a newly-created position. 10 March 2020
The European Commission has approved a change to the marketing authorization for Maviret (glecaprevir/pibrentasvir) to shorten once-daily treatment duration from 12 to eight weeks in treatment-naïve, compensated cirrhotic, chronic hepatitis C virus (HCV). 6 March 2020
Cambridge, Massachusetts-based BlueRock Therapeutics has appointed Seth Ettenberg as chief scientific officer, overseeing R&D efforts based around the firm's proprietary cell and gene platform. 6 March 2020
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines. 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
The US Food and Drug Administration (FDA) has granted the Gilead Sciences subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL). 3 October 2024
Kedrion Biopharma has finalized an agreement with Germany-based Biotest for the long-term commercialization and distribution of Yimmugo (immune globulin) in the USA. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Privately-held Ferring Pharmaceuticals has announced the opening of a global manufacturing hub in Finland for the drug substance of its intravesical non-replicating gene therapy Adstiladrin (nadofaragene firadenovec-vncg). 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
The BioIndustry Association (BIA), in collaboration with the Centre for Process Innovation (CPI), has published a new report on the UK’s mRNA sector. 2 October 2024
Aspen Neuroscience, a private biotechnology company specializing in autologous cell therapies, has announced the opening of a major new facility near its headquarters in San Diego. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024